Literature DB >> 10822438

Incidence of and risk factors for hallucinations and delusions in patients with probable AD.

J S Paulsen1, D P Salmon, L J Thal, R Romero, C Weisstein-Jenkins, D Galasko, C R Hofstetter, R Thomas, I Grant, D V Jeste.   

Abstract

OBJECTIVE: To examine the incidence of and risk factors for hallucinations and delusions associated with patients clinically diagnosed with probable AD.
BACKGROUND: Estimates of the incidence of psychosis in AD range widely from 10% to 75%. The risk factors for psychosis of AD are not known, although multiple studies indicate that AD patients with psychosis demonstrate greater cognitive and functional impairment.
METHODS: The authors conducted psychiatric evaluations of 329 patients with probable AD from the University of California at San Diego Alzheimer's Disease Research Center to determine the incidence of hallucinations and delusions. They examined data from annual clinical and neuropsychological evaluations to determine whether there were specific risk factors for the development of hallucinations and delusions.
RESULTS: Using Cox survival analyses, the cumulative incidence of hallucinations and delusions was 20.1% at 1 year, 36.1% at 2, 49.5% at 3, and 51.3% at 4 years. Parkinsonian gait, bradyphrenia, exaggerated general cognitive decline, and exaggerated semantic memory decline were significant predictors. Age, education, and gender were not significant predictors.
CONCLUSIONS: The authors found a relatively high incidence of hallucinations and delusions in patients diagnosed with probable AD and suggest that specific neurologic signs, cognitive abilities, and accelerated decline may be predictive markers for their occurrence.

Entities:  

Mesh:

Year:  2000        PMID: 10822438     DOI: 10.1212/wnl.54.10.1965

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  59 in total

Review 1.  Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience.

Authors:  Sandra S Kindermann; Christian R Dolder; Anne Bailey; Ira R Katz; Dilip V Jeste
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

2.  Executive dysfunction in Alzheimer disease.

Authors:  Margaret M Swanberg; Rochelle E Tractenberg; Richard Mohs; Leon J Thal; Jeffrey L Cummings
Journal:  Arch Neurol       Date:  2004-04

3.  Incident Psychosis in Subjects With Mild Cognitive Impairment or Alzheimer's Disease.

Authors:  Elise A Weamer; Mary Ann A DeMichele-Sweet; Yona K Cloonan; Oscar L Lopez; Robert A Sweet
Journal:  J Clin Psychiatry       Date:  2016-12       Impact factor: 4.384

4.  Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study.

Authors:  G Livingston; A E Walker; C L E Katona; C Cooper
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06-26       Impact factor: 10.154

5.  Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease.

Authors:  Robyn Carson; David Craig; Dominic Hart; Stephen Todd; Bernadette McGuinness; Janet A Johnston; Francis A O'Neill; Craig W Ritchie; A Peter Passmore
Journal:  Neuromolecular Med       Date:  2008-08-12       Impact factor: 3.843

6.  Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.

Authors:  Pierre N Tariot; Lon S Schneider; Jeffrey Cummings; Ronald G Thomas; Rema Raman; Laura J Jakimovich; Rebekah Loy; Barbara Bartocci; Adam Fleisher; M Saleem Ismail; Anton Porsteinsson; Michael Weiner; Clifford R Jack; Leon Thal; Paul S Aisen
Journal:  Arch Gen Psychiatry       Date:  2011-08

7.  Prominent neuroleptic sensitivity in a case of early-onset Alzheimer disease due to presenilin-1 G206A mutation.

Authors:  Steven P Cercy; Martin J Sadowski; Thomas Wisniewski
Journal:  Cogn Behav Neurol       Date:  2008-09       Impact factor: 1.600

8.  TAR DNA-binding protein 43 pathology in Alzheimer's disease with psychosis.

Authors:  Anil Varma V Vatsavayi; Julia Kofler; Mary Ann A Demichele-Sweet; Patrick S Murray; Oscar L Lopez; Robert A Sweet
Journal:  Int Psychogeriatr       Date:  2014-03-04       Impact factor: 3.878

9.  The relationship of excess cognitive impairment in MCI and early Alzheimer's disease to the subsequent emergence of psychosis.

Authors:  Elise A Weamer; James E Emanuel; Daniel Varon; Sachiko Miyahara; Patricia A Wilkosz; Oscar L Lopez; Steven T Dekosky; Robert A Sweet
Journal:  Int Psychogeriatr       Date:  2008-09-25       Impact factor: 3.878

10.  Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study.

Authors:  Katherine A Treiber; Constantine G Lyketsos; Chris Corcoran; Martin Steinberg; Maria Norton; Robert C Green; Peter Rabins; David M Stein; Kathleen A Welsh-Bohmer; John C S Breitner; JoAnn T Tschanz
Journal:  Int Psychogeriatr       Date:  2008-02-21       Impact factor: 3.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.